🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Online adaptive SBRT

    Sun Yat-sen University

    Adaptive Radiotherapy

    phase 2 other active

    1 trial

  2. Opaganib

    Apogee Therapeutics

    Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  3. Open Label Selinexor

    Karyopharm Therapeutics Inc

    Thymoma

    phase 2 small molecule terminated

    1 trial

  4. Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion

    Lacuna Pharma Pty Ltd

    Diabetic Retinopathy, Retinal Vein Occlusion

    phase 2 other active

    1 trial

  5. Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy

    The First People's Hospital of Lianyungang

    Psoriasis

    phase 2 small molecule active

    1 trial

  6. Oral MRT-2359

    Monte Rosa Therapeutics

    NSCLC

    phase 2 small molecule active

    1 trial

  7. Oral treprostinil

    United Therapeutics Europe Ltd

    Systemic Sclerosis

    phase 2 small molecule completed

    1 trial

  8. Oral versus topical antibioitics

    United Therapeutics Europe Ltd

    Chronic Rhinosinusitis (Diagnosis)

    phase 2 small molecule terminated

    1 trial

  9. Oxycyte

    TENAX THERAPEUTICS, INC.

    Traumatic Brain Injury

    phase 2 small molecule terminated

    2 trials

  10. Oxylanthanum Carbonate

    Unicycive Therapeutics

    Chronic Kidney Disease Requiring Chronic Dialysis

    phase 2 small molecule completed

    1 trial

  11. Oxytocin

    United Therapeutics Europe Ltd

    Alcohol Use Disorder

    phase 2 small molecule completed

    1 trial

  12. Oxytocin nasal spray

    COGNITION THERAPEUTICS INC

    Oxidative Stress

    phase 2 small molecule completed

    1 trial

  13. Oxytocin nasal spray

    COGNITION THERAPEUTICS INC

    Cold Exposure

    phase 2 small molecule completed

    1 trial

  14. PACLITAXEL, Durvalumab_IJB, CARBOPLATIN, Oleclumab_IJB

    The George Institute

    Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

    phase 2 small molecule active

    1 trial

  15. PACLITAXEL, LIBTAYO 350 mg concentrate for solution for infusion., CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. PACLITAXEL, MYCOPHENOLATE MOFETIL, volrustomig, INFLIXIMAB, FLUOROURACIL, CISPLATIN

    AstraZeneca AB

    Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).

    phase 2 small molecule active

    1 trial

  17. PALONOSETRON, Jakavi 10 mg tablets, ONDANSETRON, NETUPITANT, APREPITANT, PACRITINIB, Jakavi 5 mg tablets, SELINEXOR

    Karyopharm Therapeutics Inc

    moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis

    phase 2 small molecule active

    1 trial

  18. PARP inhibitor 2X-121

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  19. PAXALISIB

    KAZIA THERAPEUTICS LTD

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  20. PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation

    The First People's Hospital of Lianyungang

    Locally Advanced Perihilar Cholangiocarcinoma

    phase 2 other active

    1 trial

  21. PD-1 Inhibitor plus Chemotherapy

    Sichuan University

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. PDC-1421 Capsule

    ABVC BIOPHARMA, INC.

    Attention-Deficit Hyperactivity Disorder (ADHD)

    phase 2 small molecule completed

    1 trial

  23. PEG-liposomal prednisolone sodium phosphate

    Lakefront Biotherapeutics NV

    Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

  24. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources